CT032
/ CARsgen, Korea Kolmar
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
April 14, 2023
Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma
(clinicaltrials.gov)
- P1/2 | N=20 | Completed | Sponsor: CARsgen Therapeutics Co., Ltd. | Recruiting ➔ Completed | N=78 ➔ 20
CAR T-Cell Therapy • Enrollment change • Trial completion • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CXCL8 • IL10 • IL2 • IL6
October 07, 2020
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
(clinicaltrials.gov)
- P=N/A; N=18; Active, not recruiting; Sponsor: Kang YU; Recruiting ➔ Active, not recruiting; N=48 ➔ 18; Trial completion date: Dec 2021 ➔ Dec 2023; Trial primary completion date: Dec 2019 ➔ Dec 2020
Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Esophageal Cancer • Follicular Lymphoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Hepatology • Leukemia • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Pancreatic Cancer • Solid Tumor • CD19
November 14, 2019
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
(clinicaltrials.gov)
- P=N/A; N=48; Recruiting; Sponsor: Kang YU; Not yet recruiting ➔ Recruiting; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Jun 2019 ➔ Dec 2019
Clinical • Enrollment open • Trial completion date • Trial primary completion date
October 01, 2019
Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma
(clinicaltrials.gov)
- P1/2; N=78; Recruiting; Sponsor: Carsgen Therapeutics, Ltd.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
June 21, 2019
Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma
(clinicaltrials.gov)
- P1/2; N=78; Not yet recruiting; Sponsor: Carsgen Therapeutics, Ltd.
Clinical • New P1/2 trial
1 to 5
Of
5
Go to page
1